Intraocular chemotherapy for vitreoretinal lymphoma: a review

Michael Kvopka, Stewart Lake, Justine Smith

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
Original languageEnglish
Pages (from-to)240-248
Number of pages9
JournalClinical and Experimental Ophthlamology
Volume48
Issue number2
Early online date3 Nov 2019
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • drug therapy
  • eye
  • vitreoretinal lymphoma
  • retina
  • intraocular chemotherapy
  • lymphoma

Fingerprint Dive into the research topics of 'Intraocular chemotherapy for vitreoretinal lymphoma: a review'. Together they form a unique fingerprint.

Cite this